FLNA
ENSG00000196924
Target class
Unclassified protein
Chromosome
X
Approved drugs
0
Clinical candidates (approved and in development)
1
- Approved drugs
- 0
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 1
- Chemical probe available
- No
- Other names
- ABP-280
- Target name
- FLNA
- Gene name
- Filamin A
- Gene symbol
- FLNA
- Protein name
- Filamin-A (FLN-A) (Actin-binding protein 280) (ABP-280) (Alpha-filamin) (Endothelial actin-binding protein) (Filamin-1) (Non-muscle filamin)
- FLN1
- FLN
- OPD2
- OPD1
- Gene biotype
- Protein coding
- Gene family
- Filamin family
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 4,950.86
- Tissue specificity (Gini)
- 0.697
- Tissue specificity (tau)
- 0.854
- KEGG gene identifiers
- hsa:2316
- Protein interaction confidence
- 0.840545
- Protein interaction partners
- 101
- R-HSA-114608
- R-HSA-430116
- R-HSA-446353
- R-HSA-5627123
- R-HSA-8983711
- End position
- 154374638
- Start position
- 154348524
- Chromosome
- X
- Strand
- Reverse
- Cytoplasm, cell cortex . Cytoplasm, cytoskeleton . Perikaryon . Cell projection, growth cone . Cell projection, podosome . Note=Colocalizes with CPMR1 in the central region of DRG neuron growth cone (By similarity). Following SEMA3A stimulation of DRG neurons, colocalizes with F-actin (By similarity). Localized to the core of myotube podosomes (By similarity). .
- Actin filaments
- Cytosol
- Plasma membrane
Publication evidence
- PubMed 16291724
- Tissue specificity (tau)
- 0.853632
- Expression inequality (Gini)
- 0.697499
Expression in transcripts per million
- Artery - Tibial
- 4,950.86
- Colon - Sigmoid
- 3,958.63
- Esophagus - Muscularis
- 3,824.37
- Artery - Aorta
- 3,732.42
- Esophagus - Gastroesophageal Junction
- 3,727.98
Expression in transcripts per million
- Artery - Tibial4,950.86
- Colon - Sigmoid3,958.63
- Esophagus - Muscularis3,824.37
- Artery - Aorta3,732.42
- Esophagus - Gastroesophageal Junction3,727.98
- Uterus2,918.58
- Artery - Coronary2,747.03
- Bladder2,335.29
- Fallopian Tube2,233.5
- Cervix - Endocervix1,397.7
- Colon - Transverse1,065.11
- Cervix - Ectocervix1,014.89
- Prostate942.08
- Cells - Cultured fibroblasts931.78
- Lung700.52
- Vagina696.82
- Nerve - Tibial632.23
- Ovary615.82
- Adipose - Subcutaneous524.05
- Breast - Mammary Tissue401.9
- Adipose - Visceral (Omentum)380.38
- Esophagus - Mucosa326.73
- Small Intestine - Terminal Ileum309.96
- Spleen265.18
- Skin - Sun Exposed (Lower leg)255.98
And 29 more, listed on the interactive page.
- GO:0007195
- GO:0016479
- GO:0030036
- GO:0030334
- GO:0034394
- GO:0042177
- GO:0042307
- GO:0043066
- GO:0043113
- GO:0043123
- GO:0044319
- GO:0045184
- GO:0050821
- GO:0051764
- GO:0060271
- GO:0070527
- GO:0071526
- GO:0072659
- GO:0090042
- GO:0090307
- GO:1900026
- GO:1901381
- GO:1905000
- GO:2001046
- GO:0005576
- GO:0005634
- GO:0005730
- GO:0005737
- GO:0005829
- GO:0005886
- GO:0005911
- GO:0005925
- GO:0015629
- GO:0016020
- GO:0031523
- GO:0070062
- GO:0001664
- GO:0003723
- GO:0005515
- GO:0015459
- GO:0019900
- GO:0031267
- GO:0034988
- GO:0042803
- GO:0044325
- GO:0045296
- GO:0051015
- GO:0051020
- GO:0140297
- GO:0140311
Related records
Trials (11)
- A Pharmacokinetic Study of Simufilam in Subjects With Impaired Hepatic Function
- A Safety Study of PTI-125 in Healthy Volunteers
- Food Effect and Bioequivalence Study of Simufilam Tablets in Healthy Volunteers
- Open-label Extension for Phase 3 Clinical Trials of Simufilam
- Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease
- Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Simufilam Following a Single Oral Dose in Healthy Male Subjects
- PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
- PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
- Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients
- Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease
- Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease
Drugs (1)
- Simufilam Filamin-A positive modulator